Filing Details
- Accession Number:
- 0001209191-14-032428
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-05-08 21:29:02
- Reporting Period:
- 2014-05-07
- Filing Date:
- 2014-05-08
- Accepted Time:
- 2014-05-08 21:29:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178253 | Scynexis Inc | SCYX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1163156 | Alta Biopharma Partners Ii Lp | One Embarcadero Center, 37Th Floor San Francisco CA 94111 | No | No | Yes | No | |
| 1163157 | Alta Embarcadero Biopharma Partners Ii Llc | One Embarcadero Center, 37Th Floor San Francisco CA 94111 | No | No | Yes | No | |
| 1163189 | Alta Biopharma Management Ii Llc | One Embarcadero Center, 37Th Floor San Francisco CA 94111 | No | No | Yes | No | |
| 1198321 | Farah Champsi | One Embarcadero Center, 37Th Floor San Francisco CA 94111 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-05-07 | 4,551 | $0.20 | 4,551 | No | 4 | X | Direct | |
| Common Stock | Acquisiton | 2014-05-07 | 4,551 | $0.20 | 9,102 | No | 4 | X | Direct | |
| Common Stock | Acquisiton | 2014-05-07 | 82,454 | $0.20 | 91,556 | No | 4 | X | Direct | |
| Common Stock | Acquisiton | 2014-05-07 | 161,238 | $0.00 | 252,794 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2014-05-07 | 50,239 | $0.00 | 303,033 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2014-05-07 | 69,476 | $0.00 | 372,509 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2014-05-07 | 868,066 | $10.00 | 1,240,575 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2014-05-07 | 174 | $0.20 | 174 | No | 4 | X | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| Common Stock | Acquisiton | 2014-05-07 | 174 | $0.20 | 348 | No | 4 | X | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| Common Stock | Acquisiton | 2014-05-07 | 3,033 | $0.20 | 3,381 | No | 4 | X | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| Common Stock | Acquisiton | 2014-05-07 | 5,931 | $0.00 | 9,312 | No | 4 | C | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| Common Stock | Acquisiton | 2014-05-07 | 1,848 | $0.00 | 11,160 | No | 4 | C | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| Common Stock | Acquisiton | 2014-05-07 | 2,642 | $0.00 | 13,802 | No | 4 | C | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| Common Stock | Acquisiton | 2014-05-07 | 31,934 | $10.00 | 45,736 | No | 4 | P | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | X | Direct | |
| No | 4 | X | Direct | |
| No | 4 | X | Direct | |
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct | |
| No | 4 | X | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| No | 4 | X | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| No | 4 | X | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| No | 4 | C | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| No | 4 | C | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| No | 4 | C | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
| No | 4 | P | Indirect | By Alta Embarcadero BioPharma Partners II, LLC |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Common Stock Warrant (right to buy) | Disposition | 2014-05-07 | 4,551 | $0.00 | 4,551 | $0.20 |
| Common Stock | Common Stock Warrant (right to buy) | Disposition | 2014-05-07 | 4,551 | $0.00 | 4,551 | $0.20 |
| Common Stock | Common Stock Warrant (right to buy) | Disposition | 2014-05-07 | 82,454 | $0.00 | 82,454 | $0.20 |
| Common Stock | Series C Preferred Stock | Disposition | 2014-05-07 | 570,159 | $0.00 | 161,238 | $0.00 |
| Common Stock | Series D-1 Preferred Stock | Disposition | 2014-05-07 | 1,024,876 | $0.00 | 50,239 | $0.00 |
| Common Stock | Series D-2 Preferred Stock | Disposition | 2014-05-07 | 1,417,315 | $0.00 | 69,476 | $0.00 |
| Common Stock | Common Stock Warrant (right to buy) | Disposition | 2014-05-07 | 174 | $0.00 | 174 | $0.20 |
| Common Stock | Common Stock Warrant (right to buy) | Disposition | 2014-05-07 | 174 | $0.00 | 174 | $0.20 |
| Common Stock | Common Stock Warrant (right to buy) | Disposition | 2014-05-07 | 3,033 | $0.00 | 3,033 | $0.20 |
| Common Stock | Series C Preferred Stock | Disposition | 2014-05-07 | 20,975 | $0.00 | 5,931 | $0.00 |
| Common Stock | Series D-1 Preferred Stock | Disposition | 2014-05-07 | 37,702 | $0.00 | 1,848 | $0.00 |
| Common Stock | Series D-2 Preferred Stock | Disposition | 2014-05-07 | 53,915 | $0.00 | 2,642 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2011-12-07 | 2016-12-06 | No | 4 | X | Direct |
| 0 | 2012-05-15 | 2017-05-14 | No | 4 | X | Direct |
| 0 | 2013-12-11 | 2018-12-10 | No | 4 | X | Direct |
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | 2011-12-07 | 2016-12-06 | No | 4 | X | Indirect |
| 0 | 2012-05-15 | 2017-05-14 | No | 4 | X | Indirect |
| 0 | 2013-12-11 | 2018-12-10 | No | 4 | X | Indirect |
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Farah Champsi (known as the "Principal") is the managing director of Alta BioPharma Management II, LLC ("ABM II") (which is the general partner of Alta BioPharma Partners II, L.P. ("ABP II")), and manager of Alta Embarcadero BioPharma Partners II, LLC ("AEBP II"). As managing director and manager of such entities, Ms. Champsi may be deemed to have voting and investment power for the shares held by ABP II and AEBP II. The Principal disclaims beneficial ownership of all such shares held by ABP II and AEBP II, except to the extent of her proportionate pecuniary interests therein.
- These securities are held by AEBP II.
- Upon closing of the Issuer's initial public offering, each share of Series C Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-3.536 basis, and had no expiration date.
- Upon closing of the Issuer's initial public offering, each share of Series D-1 Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-20.4 basis, and had no expiration date.
- Upon closing of the Issuer's initial public offering, each share of Series D-2 Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-20.4 basis, and had no expiration date.
Billionaire Hedge Funds
